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Biology has been revolutionized by tools that allow
the detection and characterization of protein-protein
interactions (PPIs). Fo¨rster resonance energy trans-
fer (FRET)-based methods have become particularly
attractive as they allow quantitative studies of PPIs
within the convenient and relevant context of living
cells. We describe here an approach that allows the
rapid construction of live-cell FRET-based binding
curves using a commercially available flow cytome-
ter. We illustrate a simple method for absolutely cal-
ibrating the cytometer, validating our binding assay
against the gold standard isothermal calorimetry
(ITC), and using flow cytometric FRET to uncover
the structural and functional effects of the Cushing-
syndrome-causing mutation (L206R) on PKA’s cata-
lytic subunit. We discover that this mutation not
only differentially affects PKAcat’s binding to its mul-
tiple partners but also impacts its rate of catalysis.
These findings improve our mechanistic understand-
ing of this disease-causing mutation, while illus-
trating the simplicity, general applicability, and
power of flow cytometric FRET.
INTRODUCTION
Interactions between proteins underlie much of the richness and
complexity of biology. Proteins rarely act in isolation; rather, their
function is often modulated, regulated, or localized by their inter-
actions with other proteins (Robinson et al., 2007). Many biolog-
ical processes, from signal transduction to synaptic vesicle
release, require the sequential binding and unbinding of a
network of proteins to achieve their intended effects. Conse-
quently, techniques for detecting and characterizing protein-
protein interactions (PPIs) have been instrumental in advancing
our understanding of biology.
These methods are broadly divided into techniques that
probe PPIs under extracellular or intracellular conditions. The
former group includes biochemical assays, surface plasmonCellresonance (SPR), and isothermal calorimetry (ITC), which are
generally highly quantitative but are relatively low throughput
and can be limited by the demands of isolating and purifying suf-
ficient quantities of high-quality protein. The latter group in-
cludes techniques like two-hybrid assays, which are higher
throughput and have the advantage of interrogating proteins
within an intracellular milieu but are less quantitative with higher
rates of false positives and false negatives (Br€uckner et al.,
2009). More recently, Fo¨rster resonance energy transfer
(FRET)-based methods have gained popularity (Kenworthy,
2001), as they combine the ease and biological relevance of
in-cell approaches with the specificity and quantitative power
of biochemical assays.
For instance, quantitative FRET has been used successfully to
characterize PPIs through the construction of live-cell FRET-
based binding curves (Chen et al., 2007; Erickson et al., 2003).
Imagine a scenario where proteins A and B bind to form AB
with dissociation constant KD, as illustrated in Figure 1A. Tradi-
tional approaches to characterize their binding would do so by
manually titrating one species against a fixed concentration of
the other while measuring the amount of bound product formed.
In the live-cell FRET-based approach, proteins A and B are first
tagged with fluorescent proteins that have high FRET potential,
such as the GFP variants Cerulean (Rizzo et al., 2004) (Cer)
and Venus (Nagai et al., 2002) (Ven), and expressed in live cells.
The stochastic expression of A and B in different cells then re-
sults in a natural titration of the two species, with the genetically
tagged Ven and Cer reporting the concentrations of A, B, and AB
within each cell through their direct fluorescence and the amount
of FRET. With an appropriate binding model, a binding curve can
then be constructed, with each cell contributing a point on the
graph (Figure 1B). As a result, a good estimation of binding affin-
ity typically requires interrogation of a large number of cells ex-
pressing a wide range of concentrations around the KD. Prior
attempts to apply this methodology utilized wide-field fluores-
cence microscopy to measure fluorescences and FRET effi-
ciencies cell by cell (Chen et al., 2007; Erickson et al., 2003).
Although this approach enabled FRET-based binding studies
to be done on most fluorescence microscopes, obtaining each
binding curve was a slow and laborious task where fluorescent
cells had to be measured one at a time. Moreover, the micro-
scope required frequent and onerous calibrations to offsetReports 14, 3019–3029, March 29, 2016 ª2016 The Authors 3019
Figure 1. Flow Cytometric FRET
(A) Cartoon depicting binding partners A and B tagged with fluorescent pro-
teins Ven (monomeric Venus) and Cer (monomeric Cerulean).
(B) FRET binding curves are obtained by plotting hEi as a function of eitherAfree
or Bfree.
(C–E) HEK293T cells are cultured and transfected in 6-well plates (C), har-
vested into cytometer-compatible round bottom tubes (D), and loaded into the
flow cytometer (E).
3020 Cell Reports 14, 3019–3029, March 29, 2016 ª2016 The Authorinstrument drift. These challenges placed limits on the scope of
problems addressable by this method.
The advent of the flow cytometer, an instrument capable of
performing multichannel fluorescence measurements of single
cells in a high-throughput manner, raised hopes that FRET-
based protein interaction studies could be done more simply
and efficiently. However, quantifying FRET with flow cytometry
is challenging—acceptor photobleaching (Karpova et al., 2003)
is impractical given the sub-millisecond excitation times, while
flow cytometers capable of fluorescence lifetime measurements
(Pinsky et al., 1993; Sun and Periasamy, 2015) are currently not
widely available. Spectral methods for FRET determination pre-
dominate (Leavesley et al., 2013; Szalo´ki et al., 2013), though
most groups only estimate FRET semiquantitatively, tracking
relative increases in donor quenching or sensitized acceptor
emission, using this as a high-throughput approach to detect
PPIs (Banning et al., 2010; You et al., 2006). However, semiquan-
titative FRET measurements are easily distorted by relative
donor and acceptor expression levels (Berney and Danuser,
2003), potentially leading to erroneous estimations of binding.
Moreover, proteins that bind weakly but have a favorable FRET
conformation (e.g., aligned dipoles and shorter bound distance)
might have a similar FRET efficiency to proteins that bind
strongly, albeit with unfavorable FRET conformations. Thus,
the capability to measure binding in a dose-dependent, high-
throughput manner is important, because it not only results in
higher confidence of detecting actual binding, but also enables
large-scale studies of protein binding as with drug design and
discovery and structure-function analyses.
In this study, we describe a simple method to calibrate a
commercially available flow cytometer to perform quantitative
FRET, using this approach both to construct FRET-based bind-
ing curves of fluorescent-protein-tagged proteins and to exploit
a FRET-based activity sensor. We validate our FRET-based
binding assay by comparing our binding affinity estimates with
those obtained from ITC, and we use our method to discern
the mechanism by which a recently discovered point mutation
(L206R) in the PKA catalytic subunit results in adrenal Cushing
syndrome. Our results demonstrate the ease, efficiency, and
broad utility of flow cytometric FRET, raising expectations that
FRET-based binding assays will contribute to a new era of bio-
logical discovery.
RESULTS
Quantitative FRET with Flow Cytometry
With proper calibration and selection of fluorescent molecules,
fluorescence signals from the flow cytometer can reveal the
concentrations of each fluorescent species and the average
FRET efficiency within each cell. We chose for our experi-
ments Cer and Ven bearing monomeric A206K mutations
(Zacharias et al., 2002) because of its favorable FRET proper-
ties and compatibility with a dual violet and blue laser-equipped
flow cytometer. A brief outline of our workflow is outlined in(F) Fluorescence signals are analyzed offline using custom software to yield the
concentration of Cer, Ven, and hEi, from which binding curves can be con-
structed.
s
Figures 1C–1F; HEK293T cells within 6-well plates are trans-
fected with constructs containing Cer and/or Ven and har-
vested 16–48 hr after transfection into round bottom tubes.
Each round bottom tube is sequentially loaded onto the flow
cytometer, where cells are focused into single stream and inter-
rogated one at a time by the two lasers. The resultant fluores-
cence and laser scatter are optically filtered into multiple
channels and detected, amplified, and digitized. The recorded
data are then analyzed using custom MATLAB code according
to the sequence diagrammed in Figure 1F. Fluorescence sig-
nals from single cells (Figure S1) are converted through linear
unmixing (see Experimental Procedures and Figure S2) into
the three fundamental signals of the Cer/Ven system—direct
Cer emission (Cerdirect), direct Ven emission (Vendirect), and
sensitized Ven emission from FRET (VenFRET). Vendirect is
directly proportional to the number of Ven molecules (NVen),
while Cerdirect is proportional to the number of Cer molecules
(NCer) not quenched by FRET as follows:
Vendirect =gVenfVenNVen (Equation 1)
Cerdirect =gCerfCerNCerð1 hEiÞ; (Equation 2)
where g=ge with g encompassing the instrument-dependent,
and e the fluorophore-dependent, aspects of fluorophore excita-
tion, including laser power, attenuation by optical components,
and the extinction coefficient at the laser wavelength, whereas
f = xf with f representing the fluorophore-dependent, and x the
instrument-dependent, terms of fluorophore emission, such as
the quantum efficiency and optical filtering, as well as linear
photodetection, amplification, and digitization of fluorescence.
NVen canbedetermined once the brightness of a single Venmole-
cule ðgVenfVenÞ is known,but determination ofNCer further requires
an estimation of the average FRET efficiency hEi. The average
FRETefficiency is a functionofgand f, anddependingonwhether
it is measured with respect to the donor (Cer) or acceptor (Ven), it














Thus, absolute calibration of the flow cytometer depends on
determination of g and f for both Ven and Cer. Once obtained, to-
tal concentrations of Cer (CCer) and Ven (CVen) are calculated
from NCer and NVen after accounting for cellular volume (Fig-
ure S1F). Achieving precise accounting of the fluorescent spe-
cies expressed in live cells then allows the construction of
FRET-based binding curves.
Absolute Calibration of the Flow Cytometer
Absolute calibration is achieved when fluorescence signals can
be converted to an absolute number or concentration of fluores-
cent proteins with Equations 1 and 2. Whereas the instrument-Celldependent terms g and x are difficult to determine, the fluoro-
phore-dependent terms e and f are readily accessible (Nagai
et al., 2002; Rizzo et al., 2004). Fortunately, calibration standards
for flow cytometry with known numbers of fluorochromes are
commercially available, allowing determination of g and x. We
obtained beads conjugated with predetermined numbers of
FITC molecules, as FITC is spectrally close to Venus. We can
then absolutely calibrate our flow cytometer to the brightness
of a single FITC molecule ðgFITCfFITCÞ from the slope of the fluo-
rescence versus number of FITC molecules relation. Since the
instrument is unchanged, g and x are constant, and we can
directly calculate for the brightness of a single Ven using known
values of e and f for fully-matured Ven and FITC (Seybold et al.,





As seen with Equations 3 and 4, calculating average FRET effi-
ciencies requires the ratios of g and/or f for both Cer and Ven.
These absorption and emission ratios can be determined (Chen
et al., 2006; Nagy et al., 2005) with the following rationale: with
Cer-Ven fusion proteins, the FRET efficiency should be the
same regardless of the perspective from which it is measured,
as long as there is one acceptor for every donor molecule (Sup-
plemental Information). That is, since hEiCer = hEiVen in this sce-











Equation 6 predicts a linear relationship from which the slope
and intercept yields our desired ratios (Figure 2A). Plotting the
appropriate quantities for five Cer-Ven dimers with varying linker
lengths (from 22–228 amino acids [aa]), we initially obtained
scatter plots with significant tails toward the origin (Figure S3A).
Upon further examination, we found curiously that hEiCer , but not
hEiVen, had unexpectedly large variance (Figures S3B and S3C).
We hypothesized that this asymmetric result could be explained
by the presence of a significant fraction of non-fluorescent
immature Ven molecules, since near-invisible Ven would result
in low hEiCer without affecting hEiVen. This result highlighted for
us the importance of reducing this immature fraction for all our
experiments, as the presence of immature fluorescent proteins
leads to the underestimation of both the true FRET efficiency
(when measured from the donor’s perspective) and the actual
number of tagged proteins. We thus applied the protein synthe-
sis inhibitor cycloheximide for 2 hr prior to flow cytometric inter-
rogation, reasoning that we could reduce the immature fraction
by halting new synthesis of fluorescent proteins and allowing ex-
isting Ven molecules to fully mature. Indeed, doing so dramati-
cally reduced the variance of hEiCer , resulting in the graphs
shown in Figure 2. The plot in Figure 2B enabled us to obtain es-
timates of 0.0178 and 1.65 for gVen=gCer and fVen=fCer . These
quantities when multiplied also give the relative brightness
of Ven and Cer (at roughly 405 nm excitation and 522/30 nm
emission), thus furnishing sufficient constraints to achieve abso-
lute calibration. We tested our estimates of the absorption andReports 14, 3019–3029, March 29, 2016 ª2016 The Authors 3021
Figure 2. Calibrating the Flow Cytometer for FRET
(A) The ratios gCer=gVen and fVen=fCer can be discerned from Cer-Ven dimers of varying linker lengths using the following linear equation.
(B) Each cell expressing a particular Cer-Ven dimer is plotted as a single colored dot on the graph. Contour lines are overlaid on top of each Cer-Ven dimer to show
the areas of highest density.
(C) The mean ± SD of NVen=NCer for each dimer is plotted.
(D) Plots of hEiVen and hEiCer for the five Cer-Ven dimers, with each small dot representing data from a single cell. The large dots represent population mean ± SD.emission ratios both by examining the NCer=NVen ratio and
by plotting hEiCer and hEiVen of these dimers. Reassuringly,
NCer=NVen is near 1 (Figure 2C), and hEiCer = hEiVen for each
dimer, with dimers bearing shorter linker lengths having higher
FRET efficiencies (Figure 2D).Live-Cell FRET-Based Binding Curves
We then sought to construct FRET-based binding curves with a
test set of peptides whose binding had previously been well-
characterized by ITC (Harkiolaki et al., 2003). We created con-
structs tagged with either Cer or Ven (Figure 3A) using the exact
sequence of their peptides. After expressing them in HEK293
cells, we obtained single cell measurements of CCer, CVen and
hEi using flow cytometry. Because proteins that bind to one
another do so in hand-and-glove fashion, the bound complex
adopts a conformation with FRET efficiency Emax. Since un-
bound proteins have negligible FRET,
hEiVen =AbEmax (Equation 7)
hEiCer =DbEmax (Equation 8)3022 Cell Reports 14, 3019–3029, March 29, 2016 ª2016 The Authorwhere Ab andDb refer to the fraction of acceptor (Ven) and donor
(Cer) molecules bound. Furthermore, the 1:1 binding model has
the following analytic solution:
Ab =
ðCCer +CVen +KDÞ 
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Thus, our approach is to iteratively minimize the difference be-
tween Ab as calculated using Equations 7 and 9, or Db using
Equations 8 and 10, with the parameters Emax and KD (Figure S4).
Binding curves of Ven-SH3 (Gads, aa.256–322) with five binding
partners (SLP-76, aa 231–243; Gab1, aa 515–527; USP8, aa
403–415; SLP-76 [D236K], aa 231–243; SLP-76 [K240R], aa
231–243), are presented in Figure 3B. Each binding curve is con-
structed from a single trial where > 100,000 fluorescent cellss
Figure 3. Flow Cytometric FRET Binding Curves
(A) Diagram of the binding reaction between Ven-SH3 (Mona/Gads) and Cer-X, where X represents one of several binding partners of Mona/Gads.
(B) FRET binding curves for Ven-SH3 in complex with SLP-76, aa 231–243 (black), Gab1, aa 515–527 (green), USP8, aa 403–415 (blue), SLP-76 (D236K), aa
231–243 (cyan), and SLP-76 (K240R), aa 231–243 (red). Their respective binding affinities were KD = 0.8, 1, 4, 7, and 24 mM, with Emax = 0.39, 0.4, 0.37, 0.35, and
0.35, respectively.
(C) Comparison between dissociation constants measured by flow cytometry (y axis) and thosemeasured by ITC (x axis). On average, affinities measured by flow
cytometry are 3-fold less.were collected, with each cell contributing a dot on the plot. With
each trial taking3–5min, data for all 5 constructswerecollected in
less than 30min. Data from this large number of cells forma cloud
charting the course of each binding curve with high resolution.
Protein pairs with binding affinities within an order of magnitude
of 1 mMcanbemaximally resolved,with points decorating the en-
tiretyof thebindingcurve (Figure 3B,greenandblue).On theother
hand, binding curves of weakly binding (Figure 3B, cyan and red)
or strongly binding (Figure 3B, black) protein pairs would miss
points at both extremes (Ab or Db near 0 or 1), because of the dif-
ficulty of expressing proteins at concentrations upward of several
hundred mM in live cells, or because of the difficulty of quantifying
faintly fluorescent cells when proteins are weakly expressed.
Nonetheless, binding curves that capture a significant fraction
of the full range of binding can still yield good estimates of binding
affinities through the minimization procedure described above
(Figure S4). Analyzing binding data from all peptide pairs as-
sessed, we obtained a relation between affinity estimates using
flow cytometry and those using ITC (Figure 3C). The results
impressively demonstrate that affinities estimated with both
methods are highly correlated, though estimations with flow cy-
tometry yielded affinities that were on average 3-fold lower
than those with ITC (Figure 3C, red line). The discrepancies be-
tween these two methods might be the result of small alterations
in the energetics of binding due to the steric influence of the
comparatively large fluorescent protein tags. They might also
reflect the presence of invisible inhibitors of the binding reaction,
due to endogenous inhibitor proteins and/or non-fluorescent
immature fluorophores. Regardless of the cause, these results
show that high-resolution FRET binding curves can be con-
structed quickly and efficiently with flow cytometry, yielding esti-
mates of binding affinity comparable to those by in vitro studies.
Regulation of Protein Kinase A: Implications of a
Catalytic Subunit Mutant
Recently, a number of papers were published describing the
remarkable discovery that a large subset of patients with adrenalCellCushing syndrome harbored the same point mutation (L206R) in
the P+1 loop of the catalytic subunit of PKA (PKAcat) (Beuschlein
et al., 2014; Cao et al., 2014; Di Dalmazi et al., 2014; Goh et al.,
2014; Sato et al., 2014). This mutation was found to increase
baseline PKA activity, and the gain of function was largely
thought to be due to disruption of binding between PKAcat and
its regulatory subunit (PKAreg). However, there remained doubt
as to whether some residual binding was preserved, given that
PKI, whose binding interface with PKAcat structurally resembles
PKAreg, is still able to bind to and inhibit the mutant PKAcat
(Cao et al., 2014). We thus sought to resolve this question, using
flow cytometric FRET to perform both binding and functional
studies to understand how the L206R mutation affects PKAcat’s
ability to interact with its various partners and thus alter its
function.
We first tagged PKAcat and PKAreg with Ven and Cer and per-
formed our flow cytometric live-cell FRET binding assay as
before. In this case, however, a 2:2 bindingmodel (Supplemental
Information) was used because the PKA holoenzyme forms a
tetrameric complex (Taylor et al., 2013). The results indicate
clear binding between the two wild-type subunits, with cells lin-
ing the binding curve (Figure 4A). The binding affinity was lower
than anticipated (Cheng et al., 2001), likely because of the abun-
dance of endogenous PKA in HEK293 cells. Nevertheless, flow
cytometric analysis of the mutant L206R catalytic subunit
demonstrated complete disruption of binding with the R1a reg-
ulatory domain throughout the entire range of expression (Fig-
ure 4B). Experiments with the R2b regulatory subunit yielded
similar results (Figures S5A and S5B). We then assessed binding
between PKAcat and its natural inhibitor PKI. A FRET binding
study of PKI-Ven with the wild-type Cer-PKAcat was obtained
(Figure 4C), which showed clear binding (KD = 3.5 mM), though
again with lower affinity than in vitro values (Scott et al., 1985)
due to competition from endogenous proteins. Assessing bind-
ing of PKI with L206R PKAcat (Figure 4D), we found surprisingly
that binding was preserved, though with weaker affinity (KD =
10 mM). Thus, these experiments show that the interfacialReports 14, 3019–3029, March 29, 2016 ª2016 The Authors 3023
Figure 4. Differential Effects on Binding by PKAcat L206R
(A) Fluorescent-protein tagged PKAcat and PKAreg fall on a FRET binding curve, with Emax = 0.46 and KDz1.7 mM.
(B) Binding curves between PKAcat (L206R) and PKAreg show complete lack of binding.
(C and D) Similarly, these scatter plots show binding curves between PKI and either PKAcat (C) or PKAcat L206R (D), both of which bind with Emax = 0.16, and KD =
3.5 and 10 mM, respectively.L206R mutation differentially affects PKAcat’s interactions with
two of its natural binding partners.
The partner-specific effects of L206R on PKAcat binding sug-
gested that the rate of phosphorylation of its targets might also
be affected, as transient binding of PKAcat to its substrate is a
prerequisite to catalysis. We thus sought to examine the func-
tional consequence of this mutant PKAcat using the FRET-
based PKA activity sensor AKAR4 (Depry et al., 2011). Figure 5A
diagrams a kinetic scheme of AKAR4, with AKAR4 phosphory-
lation requiring an intermediate enzyme-substrate bound state
reached through dissociation constant k1/k1 and departed
through catalytic rate constant k2. Dephosphorylation by
endogenous phosphatases is represented by a single rate con-
stant k3. Because AKAR4 exists primarily in two states—un-
phosphorylated (Emin) or phosphorylated (Emax)—the average
FRET efficiency of a cell expressing AKAR4 is linearly related
to the fraction of AKAR4 phosphorylated (P) by the following
equation:
hEi=P,Emax + ð1 PÞ,Emin (Equation 11)3024 Cell Reports 14, 3019–3029, March 29, 2016 ª2016 The AuthorEmin can be approximated by expressing AKAR4 in live cells
and applying the PKA inhibitor H-89 (thus driving k2 to 0)
while measuring FRET with flow cytometry (Figure 5B, black).
On the other hand, we can get close to Emax by overexpressing
PKAcat (Figure 5B, red). Surprisingly, hEi, which should be
independent of substrate concentration (Equation 11), ap-
peared to increase with AKAR4 expression. We reasoned this
was likely because cells expressing more AKAR4 tend to
have higher PKAcat expression as well. Indeed, PKAcat levels








where Pmax = k2=ðk2 + k3Þ, Ke =Kmð1 PmaxÞ, and Km = ðk1 +
k2Þ=k1. We estimated k3 with flow cytometry by examining the
time-dependent decay of themean population hEi of cells co-ex-
pressing AKAR4 and PKAcat after exposure to 100 mMH-89 (Fig-
ure 5C). We examined cells expressing > 4 mM AKAR4 to ensures
Figure 5. Enzyme Kinetics of PKA L206R Revealed through FRET-Based PKA Sensor
(A) Diagram illustrating the different states of the PKA activity sensor AKAR4. In its unphosphorylated state, it has low FRET (Emin). Phosphorylation through a
Michaelis-Menten scheme (k1, k1, k2) results in a state of high FRET (Emax). Dephosphorylation (k3) occurs through endogenous phosphatases.
(B) Scatter plot of single cell FRET efficiency as a function of AKAR4 expression, either with PKAcat overexpressed (red) or with H-89 (100 mM) in the solution
(black).
(C) H-89 (100 mM)was added to cells expressing AKAR4 and PKAcat at time zero.Whilemeasurements of Cer and Ven concentrations were unaffected by addition
of H-89 (top), hEi declined exponentially with t = 33 s (red curve).
(D) Scatter plot of single cell FRET efficiency versus concentration of mCherry-tagged proteins. PKI-expressing cells (black) have hEi near Emin. Expression of
mCherry-PKAcat (red) resulted in hEi increasing to near Emax, while expression of mCherry-PKAcat (L206R) resulted in a gentler ascent of hEi to a lower plateau.
(E) Scheme outlining the addition of an inhibitor. KI represents the dissociation constant of the inhibitor, whereas Ke represents the ‘‘aggregate dissociation
constant’’ for the AKAR4 system.
(F) Solution to the model diagrammed in (E), where P (percent of AKAR4 phosphorylated) is plotted versus Ctot/Itot (PKAcat to inhibitor ratio) for different values
of KI/Ke.
(G andH) Single cell FRET efficiencies of cells transfected with PKAreg together with either PKAcat (G) or PKAcat (L206R) (H). Mean results of either PKAcat (L206R in
H) or PKAreg alone are represented by thick black lines, with their kernel density estimates overlaid in red or green.
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all cells probed started with saturating PKA activity, and we esti-
mated from the exponential decay that k3 0.03 s1.
Equation 12 suggested a revealing relationship between
AKAR4 phosphorylation and PKAcat, and we thus sought to ac-
quire a means of tracking cellular PKAcat levels, while continuing
to monitor PKA activity with Cer-Ven FRET. We found that fully
matured mCherry fulfilled this role beautifully, as it was excitable
with the 488-nm laser with insignificant bleedthrough into other
channels (Figures S2I–S2K). Additionally, mCherry levels can
be estimated after accounting for Ven spectral overlap, and sin-
gle fluorophore brightness calibration with a Cer-mCherry dimer
(Figure S2L). Having added additional bandwidth to our flow cy-
tometric system, we first co-expressed in live cells mCherry-
tagged PKI with AKAR4 and obtained a largely flat FRET versus
mCherry-PKI curve, where we find that increasing expression of
mCherry-PKI depressed hEi to Emin (Figure 5D, black). On the
other hand, co-expression of mCherry-tagged PKAcat and
AKAR4 yielded a curve (Figure 5D, red) that satisfies Equation
12 with ymax = 0.445 and Ke = 0.1 mM. A similar experiment
with mCherry-tagged mutant (L206R) PKAcat instead yielded a
markedly different curve (Figure 5D, green) with ymax,mut =
0.385 and Ke,mut = 12 mM. The reduction in ymax,mut and 100-
fold increase in Ke,mut suggests that the L206R mutation
not only weakens the catalytic subunit’s interaction with
AKAR4 (k1,mut << k1) but also impairs catalysis (k2,mut < k2). Since
k2 >> k1, our estimates of k3 allow us to approximate
k1zk3=Ke = 1 3 10
5 M1s1 and k1,mut z 0.8 3 10
3 M1s1.
On the other hand, precise quantification of k2 is more difficult,
with Emax too close to ymax (Pmax 1) to be resolved. Nonethe-
less, based on prior biochemical studies (Moore et al., 2003),
we can assume k2 20 s1, which yields k2,mut 0.1 s1.
Addition of an ‘‘inhibitor,’’ such as PKAreg or PKI, to the
PKAcat + AKAR4 system results in a scheme diagrammed in Fig-
ure 5E. The inhibitor competitively binds to PKAcat, effectively
reducing the number of catalytic molecules that can phosphory-
late AKAR4. The solution to this system reveals an interesting
feature of the PKA regulatory system (Figure 5F)—the fraction
of AKAR4 phosphorylated depends not only on the relative num-
ber of catalytic and regulatory subunits (Ctot/Itot) but also on the
relative rates of PKAreg-PKAcat binding and AKAR4 cycling
(KI/Ke) (Supplemental Information). It is intuitive that Ctot/Itot < 1
is required for baseline suppression of PKAcat activity since there
has to be at least one regulatory subunit for every catalytic sub-
unit. On the other hand, KI/Ke reflects the competition between
PKAreg and substrate for PKAcat, describing the predilection of
PKAcat for either participating in the phosphorylation or quies-
cent pathway. When KI/Ke << 1 (Figure 5F, red), PKAcat strongly
prefers PKAreg and so is mostly inactive even whenCtot/Itot is just
under 1. On the other hand, if KI/Ke >> 1 (Figure 5F, green), as
would be the case with PKAcat and (cAMP)2-PKAreg, PKAcat is
mostly active, even when outnumbered by regulatory subunits.
Furthermore, this model predicts that examining AKAR4 phos-
phorylation when both PKAcat and R1a are expressed in
HEK293 cells would yield data that allow interpretation of the
relative binding affinities of PKAcat. For instance, if KI/Ke << 1,
wewould expect a bimodal FRET distributionwithmost cells dis-
playing either high or low FRET, since the steepness of the P
versus Ctot/Itot curve (Figure 5F, red) indicates that only a small3026 Cell Reports 14, 3019–3029, March 29, 2016 ª2016 The Authorfraction of cells would lie within the narrow range of Ctot/Itot
necessary for intermediate AKAR4 activity. Indeed, when we
transfect untagged PKAcat and R1a with AKAR4, we observe a
bimodal distribution of FRET activity (Figure 5G), suggesting
that KI/Ke << 1. Similarly, co-expression of PKI with wild-type
PKAcat yields a bimodal FRET distribution (Figure S5C), again
consistent with KI/Ke << 1. In contrast, co-expression of R1a
with mutant L206R PKAcat produced a unimodal distribution
(Figure 5H), suggesting that even though the L206R mutation
weakened PKAcat association with AKAR4, disruption to R1a
binding was much more severe, resulting in KI/Ke > 1 and an
inability to restrain PKAcat activity. In contrast, co-expression
of PKI with mutant L206R PKAcat recapitulates a bimodal distri-
bution (Figure S5D), showing that PKI remains capable of block-
ing L206R PKAcat activity. This is consistent with the earlier
findings of weakened yet persistent binding between mutant
PKAcat and PKI (Figure 4D). Thus, these functional experiments
reveal that the mutation L206R in the critical P+1 loop of PKAcat
is consequential not only with regards to its interactions with its
regulators and inhibitors but also its substrates.
DISCUSSION
This study reports the use of the flow cytometer for quantitative
live-cell FRET, demonstrating its utility both in providing a high-
throughput assay for measuring protein-protein binding affinities
and in revealing biological mechanisms through population-
based analyses with FRET-based sensors. We show a simple
procedure for absolute calibration of a commercially available
flow cytometer, using it to construct live-cell FRET binding
curves that yield binding affinities comparable to those from
ITC. With flow cytometric FRET, we demonstrate that a mutation
in PKAcat differentially affects its interaction with its binding part-
ners, resulting in unregulated, but slowed, catalysis of certain
substrates. These results demonstrate that flow cytometric
FRET represents a simple, fast, and powerful approach to inter-
rogating protein binding and function, providing an important
adjunct to traditional biochemical tools. The increasing afford-
ability, accessibility, and capabilities of flow cytometry in recent
years raise expectations that this methodology will find wide-
spread use and development for years to come.
Strengths and Limitations of Flow Cytometric FRET
The major advantages of this strategy over in vitro approaches
stem from the use of living mammalian cells as biochemical re-
actors. Proteins expressed in living mammalian cells receive
the support of chaperones and accessory proteins, maturing
with appropriate post-translational modifications, and thus
tend to remain more stable within their native cellular contexts
than without. With lengthy and costly protein purifications
rendered unnecessary, binding assays can be accomplished
with greater ease and speed, making larger-scale studies of
PPIs under various pharmacologic or genetic manipulations
more practical. In addition to protein binding, flow cytometric
FRET also permits population-level analyses of biological func-
tion in living cells via the ever-growing list of FRET-based biosen-
sors. All in all, it is the strict accounting of every fluorescent
species in addition to the FRET efficiency within each cells
afforded by this approach that enables the engagement of bio-
logical problems from a quantitative and model-based perspec-
tive. In this light, our work here represents a few ofmany possible
applications of flow cytometric FRET, and we anticipate that
uses beyond those suggested here will continue to surface,
especially when coupled with cytometers with sorting capabil-
ities or automated flow cytometric platforms.
Assaying binding with flow cytometric FRET is not without lim-
itations. These include the necessity of altering proteins with
fluorescent protein tags and the interference by unaccounted
endogenous proteins. In many cases, the former problem is sur-
mountable as protein tags can be designed such that they do not
affect native protein function, in accordance with the modular
nature of many proteins. The unwanted contribution of endoge-
nous proteins, on the other hand, typically have their highest
impact on high-affinity interactions, as their effects can usually
be minimized by the overexpression of fluorescently tagged re-
combinant proteins. If necessary, genetic strategies for knocking
down endogenous protein levels can also be employed. Finally,
the high-throughput measurement of single-cell fluorescence
imposes additional challenges on flow cytometric FRET. When
compared to microscope-based FRET, flow cytometric FRET
performs more poorly with dimly fluorescent cells due to the cy-
tometer’s lower signal-to-noise ratio at low fluorescent inten-
sities. This causes the flow cytometric measurement of FRET
from poorly expressing proteins, such as might be the case in
some subcellularly localized proteins, to be enveloped in noise.
However, this is a technological hurdle that we anticipate will
be overcome with brighter fluorescent reporters andmore sensi-
tive and precise instruments. A more fundamental limitation of
flow cytometric FRET relates to the need to detach cells from
their substrates for spectroscopic interrogation. Not only are
unique cell features such as cell morphology and local density
lost when cells are dissociated, but resuspending naturally
adherent cells in solution also alters aspects of a cell’s biology,
potentially affecting the proteins under study. Although these is-
sues likely affect only a minority of projects, they should be seri-
ously considered before any flow cytometric experiment.
Implications of L206R for PKA Function
We determined that the Cushing-disease-causing L206R muta-
tion within the P+1 loop of PKAcat completely disrupts its interac-
tion with PKAreg, while largely preserving its binding to PKI. The
differential effect on binding of L206R is consistent with prior
studies showing the ability of PKI, but not PKAreg, to suppress
the activity of L206R PKAcat (Cao et al., 2014; Cheung et al.,
2015). Additionally, monitoring PKA activity using the FRET-
based PKA sensor AKAR4 further reveals that this mutant PKAcat
has not only weakened binding to AKAR4 but also reduced cat-
alytic activity. These findings are not unexpected, given that
mutagenesis of other residues within the P+1 loop have been
shown to interfere with catalytic activity (Moore et al., 2003).
However, they do conflict with reports that showed equal (Cale-
biro et al., 2014) or elevated (Cheung et al., 2015) catalysis by
L206R PKAcat with the synthetic substrate Kemptide. The reason
for this discrepancy is not clear but may be due to the differential
effects of the L206R mutation on different PKA substrates.
Finally, we described a model of AKAR4 phosphorylation incor-Cellporating both substrate and inhibitor that allowed us to assess
the relative ‘‘affinities’’ for substrate versus inhibitor (KI/Ke)
through the distribution of FRET efficiencies. These experiments
independently confirmed the disparate effects on binding of
PKAcat L206R, and also illustrated the importance of an interme-
diary Ke for optimal switching of PKA activity. Overall, these find-
ings hold key implications for understanding the pathogenesis of




All cDNA plasmid constructs used in this study have transcription driven by the
CMV promoter. Plasmids encoding monomeric Cerulean (Cer-C1) and Venus
(Ven-C1) as well as dimers C32V, C40V, C50V, and CTVwere gifts fromSteven
Vogel (NIH). Cer-N3, Ven-N3, and mCherry-N3, with multiple cloning sites
N-terminal to the fluorescent proteins, were generated through PCR amplifica-
tion of the fluorescent proteins (startless) using primers P01/P02 (primers listed
in Supplemental Information) from Cer-C1, Ven-C1, and mCherry-C1 (Clon-
tech) and insertion into EGFP-N3 (Clontech) with BamHI/BsrGI. These C1
and N3 plasmids serve as the backbones to which other proteins can be fused
to Cer or Ven at either terminus. C22V and C22R were generated by cutting
and inserting from Ven-N3 ormCherry-N3 into Cer-C1with BglII/XbaI. The car-
boxy-terminal SH3 domain from Mona/Gads was PCR amplified from mouse
tail DNA with P03/P04 and inserted into Ven-C1 with BglII/HindIII. Its various
Cer-tagged 13 amino acid binding partners were synthesized by annealing,
cutting, and inserting cDNA primer pairs (P05-P28) bearing the desired
sequence into Cer-C1 with XhoI/HindIII. Plasmids containing human PKAcat
(pDONR223-PRKACA), PKAreg (pDONR223-PRKAR1A and pDONR223-
PRKAR2B), and PKI (pRSV-PKIv2) were obtained from http://www.addgene.
org, while AKAR4 was a gift from Jin Zhang (Hopkins). PKAcat was PCR ampli-
fied with P29/P30 and cut with BamHI/HindIII before insertion into Cer-C1,
Ven-C1, and mCherry-C1 using BglII/HindIII to make Cer-PKAcat, Ven-PKAcat,
and mCherry-PKAcat. The L206R mutation in PKAcat was made using overlap-
extension PCR with overlap primers P31/P32 and flank primers P29/P30, with
reinsertion using EcoRV/XhoI. PKAreg-Cer and PKAreg-Ven were made by PCR
amplification of PKAreg R1a (P33/P34) or PKAreg R2b (P35/P36) and insertion
into Cer-N3 and Ven-N3 with KpnI/BamHI or KpnI/BamHI/BglII, respectively.
PKI-Cer, PKI-Ven, and PKI-mCherry were constructed by PCR amplification
using P37/P38 and insertion into Cer-N3, Ven-N3, or mCherry-N3 using
KpnI/BamHI. Untagged PKAcat was made by PCR amplification using P39/
P40 and insertion into pcDNA3.1 (Invitrogen) using KpnI/XbaI, while untagged
PKAreg (R1a) was made by cutting PKAreg-Cer (R1a) and inserting into Cer-C1
with KpnI/BamHI. All constructs were verified by restriction digest and Sanger
sequencing.
Cell Culture, Transfection, and Preparation for Flow Cytometry
HEK293 and HEK293T cells were cultured using sterile techniques on 6-well
plates at 37C with 5% CO2. Our culture media contained DMEM (Invitrogen)
supplemented with 10% FBS, 5 mM L-glutamine, 50 units/ml penicillin, and
50 mg/ml gentamicin. Cells within each well were transiently transfected at
75% confluency using polyethylenimine (Polysciences) with a 3:1 (PEI:DNA)
ratio. 16–48 hr after transfection, cells were trypsinized and transferred to
1.6-ml microcentrifuge tubes where they were washed twice and then resus-
pended in 500 ml of HEPES-buffered Tyrode’s solution. Cells were then trans-
ferred to 5-ml round bottom polystyrene tubes for use in the flow cytometer. In
most experiments, 100 mM cycloheximide was added to cells 2–4 hr prior to
flow cytometric interrogation to halt new protein synthesis, allowing immature
fluorescent proteins to fully mature.
Flow Cytometry
We used an Attune acoustic focusing flow cytometer (Life Technologies)
equipped with violet (405 nm) and blue (488 nm) lasers. Forward and side scat-
ter signals were developed from the violet laser and used to gate for single,Reports 14, 3019–3029, March 29, 2016 ª2016 The Authors 3027
healthy cells. SCer and SFRET channels were taken from the violet laser, while
SFRET and Sred were off the blue laser. Optical filters used for SCer, SVen, SFRET,
and Sred were 450/40, 530/30, 522/31, and 603/48, respectively. Flow cyto-
metric signals were collected using ‘‘high-sensitivity’’ mode at a flow rate of
100 ml/min. Cells are illuminated for 40 ms by each of the two lasers, with a
time-of-flight of 1.2 ms from the violet to the blue laser. We confirmed that
there was no appreciable photoactivation of Venus by violet (405 nm) light
(data not shown). Maintenance and performance tracking of the flow
cytometer were performed with Attune performance tracking beads (Life
Technologies) in accordance with manufacturer’s specifications. FITC beads
used for absolute calibration and for calibration across PMT voltages were
Quantum FITC-5 MESF (Bangs Laboratories). Fluorescence data were ex-
ported as FCS files for further processing with custom MATLAB (MathWorks)
software.
Several control experiments were prepared every time the flow cytometer
was used: cells exposed to PEI but without plasmids served as our blank con-
trols and were used to define the background level for each channel (BGCer,
BGVen, BGFRET, BGRed); Cer, Ven, and mCherry each expressed by itself gives
the proportionality constants (RD1, RD2, RD3, RA1, RA2, RC) for spectral unmix-
ing; and Cer and Ven expressed together provides an estimate of the concen-
tration-dependent collisional FRET (Figures S2M–S2R). The series of Cer-Ven
dimers for gA/gD and fA/fD calibration were performed monthly, while calibra-
tion with Quantum beads were used only when the flow cytometer has drifted
significantly from baseline, as determined by serial performance testing.Data Processing
Our custom software serves the following three functions: (1) as a means to
organize experimental constructs by name, type, and date, (2) to determine
and store the necessary instrument- and fluorophore-dependent constants,
and (3) to transform the raw fluorescence values into FRET efficiencies and
binding curves, as outlined in Figure 1F. For all samples, single cells are first
selected through sequential gating with forward- and side-scatter plots (Fig-
ures S1A–S1C). Background levels are determined from blank cells by taking
the mean fluorescence levels of each channel after discarding 1% of outliers
and are used for background subtraction in all subsequent analysis (Figures
S1D and S1E).RA1 andRA2 were taken from Ven-only cells (Figure S2A) by tak-
ing the slope of a linear regression of SFRET versus SVen, and SFRET versus SRed
(Figures S2C and S2D). Similarly, RD1, RD2, and RD3 are determined Cer-only
cells with SFRET versus SCer, SVen versus SCer, and SRed versus SCer, respec-
tively (Figures S2E–S2H). Importantly, these relations between channels
become supralinear at very high fluorescence intensities (Figure S2B), likely
due to inner filter effects, and so highly expressing cells were excluded from
analysis. Moreover, to minimize the influence of outliers, binned median fluo-
rescences were used to calculate the linear regressions from which the pro-
portionality constants (RD1, RD2, RD3, RA1, RA2) are determined. The unmixed
signals (Cerdirect, Vendirect, VenFRET, and Cherry) were then obtained by invert-
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These unmixed quantities allow calibration of gA/gD and fA/fD using a series of
Cer-Ven dimers and Equation 6, calculation of mean cellular FRET efficiencies
according to Equations 3 or 4, as well as determination of NVen and NCer using
Equations 1 and 2. As detailed in the main text, the absolute brightness of Ven
(gAfA) was determined via comparison with FITC beads, and the brightness of
Cer (gDfD) assessed relative to that of Ven through the Cer-Ven dimer series.
We also estimated the brightness of mCherry (gChfCh) relative to Cer using a
Cer-mCherry dimer (Figure S2L), which enabled us to calculate NCherry from
Cherry. It is especially important to determine experimentally the brightness
of Cer relative to that of Ven because an accurate gauge of the brightness ratio
is so crucial to calculating the FRET efficiency. Finally, we estimated the vol-
ume of an average HEK293 cell by pipetting trypsinized HEK293 cells onto a
glass coverslip and measuring the radii of these loosely attached spherical
cells with confocal microscopy (Figure S1F).3028 Cell Reports 14, 3019–3029, March 29, 2016 ª2016 The AuthorSUPPLEMENTAL INFORMATION
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